Why Does The DEA Want This Chemical Banned?

The synthetic opioid derivative SR-17018 shows significant promise in preclinical research for opioid use disorder treatment. Unlike traditional opioid agonists, this compound acts as a G protein signaling-biased agonist at the mu-opioid receptor, which appears to restore morphine tolerance levels and prevent the onset of withdrawal symptoms in rodent models without triggering the same high or standard respiratory depression associated with conventional opioids. These unique pharmacological properties have attracted attention from researchers and patients as a potential alternative, non-recreational tool for managing withdrawal. Controversy surrounds the DEA plans to enact emergency scheduling of SR-17018 as a Schedule I substance, which places the compound in the same category as substances deemed to have high abuse potential and no currently accepted medical use. This decision effectively halts ongoing research and limits patient access to what some argue is a breakthrough in addiction treatment. Organized efforts at stop-sr17-ban.com now encourage public awareness and civic engagement, such as filing official comments or contacting congressional representatives, to challenge the proposed scheduling and protect research access.